Tango Therapeutics (TNGX) has quietly turned into a strong performer, with the stock up roughly 200% this year and more than tripling over the past year as investors reassess its oncology pipeline.

Tango Therapeutics, Inc. remains a high-risk, high-reward biotech, focused on PRMT5 inhibitors for MTAP-deleted cancers—a large, underserved market opportunity. Disappointing clinical data last ...

We are circling back on clinical stage developmental concern Tango Therapeutics, Inc. for the first time since November 2022. The company recently raised capital to fund all operations well into 2027, ...

Tango Therapeutics (TNGX) entered a sales agreement with Leerink Partners to sell up to $100M of common stock through an at-the-market offering. Leerink Partners will use commercially reasonable ...

Performances in N.Y.C. Advertisement Supported by “Tango After Dark” at the Joyce Theater feels like an extended nightclub floor show, low in imagination and musical subtlety. By Brian Seibert The ...